<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00184600 on 2005_09_15: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00184600">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00184600">&#8593; Current version of this study</a></div><h1>View of NCT00184600 on
  2005_09_15</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00184600</td>
</tr>
<tr>
<th>Updated:</th><td>2005_09_15</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 with OAD Treatment in Type 2 Diabetes</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>3 Year Efficacy and Safety Comparison of Adding Insulin Detemir, Biphasic Insulin Aspart 30 or Insulin Aspart to Oral Antidiabetic Drug Treatment in Type 2 Diabetes.</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>This trial is conducted in Europe.<br>
<br>The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to current OAD treatment in type 2 diabetes and to verify the safety of use ( number and severity of episodes of hypoglycaemia, body weight and side effects).</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 4</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Randomized</td>
</tr>
<tr>
<th>Study design</th><td>Open Label</td>
</tr>
<tr>
<th>Study design</th><td>Active Control</td>
</tr>
<tr>
<th>Study design</th><td>Parallel Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Safety/Efficacy Study</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: 
         Proportion of subjects who achieve HbA1c &le; 6.5% without hypoglycaemia in the last 4 weeks of year 1/year 3, Efficacy and durability of the insulin regimens over a 12-36months following a treatment algorithm
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         Body weight
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         Quality of Life
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         Blood glucose
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         Hypoglycaemia
      </td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: 
         Adverse events
      </td>
</tr>
<tr>
<th>Condition</th><td>
         Diabetes Mellitus, Type 2
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Insulin detemir</div>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Insulin aspart</div>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: Biphasic insulin aspart 30</div>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>
            Recruiting
         </td>
</tr>
<tr>
<th>Start date</th><td>
         2004-11
      </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Inclusion Criteria:<br> &nbsp;- Type 2 Diabetes<br> &nbsp;- Insulin naive<br> &nbsp;- On OAD treatment<br> &nbsp;- BMI &le; 40.0 kg/m2<br> &nbsp;- HbA1c7.0%-10% (both inclusive)<br>
<br>Exclusion Criteria:<br> &nbsp;- Proliferative retinopathy<br> &nbsp;- Recurrent major hypoglycaemia<br> &nbsp;- Cardial problems<br> &nbsp;- Uncontrolled hypertension<br> &nbsp;- Impaired hepatic or renal function</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Minimum age</th><td>18 Years</td>
</tr>
<tr>
<th>Maximum age</th><td>N/A</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th>Expected enrollment</th><td>700</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Novo Nordisk</td>
</tr>
<tr>
<th>Organization study ID</th><td>NN304-1613</td>
</tr>
<tr>
<th>Sponsor</th><td>
               Novo Nordisk
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United Kingdom: Medicines and Healthcare Products Regulatory Agency
         </td>
</tr>
<tr>
<th>Health Authority</th><td>
               Ireland: Irish Medicines Board
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
